# Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)

> **NCT00705224** · — · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 250 (actual)

## Conditions studied

- Hepatitis C, Chronic
- Hepatitis C Virus

## Interventions

- **BIOLOGICAL:** Pegylated Interferon
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00705224
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2015-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00705224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00705224, "Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00705224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*